In-house Neuroscience R&D the Latest Cut at AstraZeneca
LONDON – AstraZeneca plc said it will spend more of its annual $5 billion R&D budget with external partners as it announced it is once again taking the ax to the in-house R&D operations, in a third phase of restructuring that will see a further 2,200 job cuts added to the 5,300 R&D posts the company has cut since 2007.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST